ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1751

Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center
Abstract Number: 1504

Four Distinct Symptom-Based Clusters Identified from the Sjӧgren’s Foundation Survey
Abstract Number: 0891

Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
Abstract Number: 0119

Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes
Abstract Number: 0422

Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica
Abstract Number: 1535

Frequency and Anatomic Distribution of Magnetic Resonance Imaging Lesions in the Sacro-iliac Joints of Healthy Subjects and Patients with Spondyloarthritis
Abstract Number: 1618

Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year
Abstract Number: 1292

Frequency and Predictors of Influenza Vaccine Hesitancy in Systemic Autoimmune Rheumatic Diseases
Abstract Number: 1164

Frequency of Genetic Diagnosis in an Autoinflammatory Disease Natural History Protocol Cohort of Patients
Abstract Number: 1559

Fully Automatic Assessment of Nail Fold Capillaroscopy Software – Early Results
Abstract Number: 1455

Functional Characterization of PLCG2 Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Antibody Deficiency and Immune Dysregulation (APLAID) Reveals Both Hypermorphic and Hypomorphic Mutants
Abstract Number: 0067

Functionally Mature CD1c+ Dendritic Cells Contribute to Synovial Inflammation in Rheumatoid Arthritis via STAT3
Abstract Number: 1181

Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients
Abstract Number: 1402

Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis
Abstract Number: 1779

Gap in Contraceptive Education to Females with Rheumatic Disease on Teratogenic Medications

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].